Back to Trial Watch
    Pivotal Trial StartedOncologyBrain Metastases

    Breast Cancer (Brain Metastases); Utidelone + Capecitabine

    Biostar Pharma; U.S. Pivotal Trial

    December 15, 2025
    5 min read

    What Happened

    Biostar Pharma announced first-patient dosing on December 15, 2025 in a U.S. pivotal clinical trial evaluating utidelone combined with capecitabine for patients with HER2-negative breast cancer with brain metastases.

    source: biospace.com

    Trial Design

    Study Design

    Two-stage pivotal trial with approximately 120 patients

    Primary Endpoint

    Intracranial objective response rate

    Site Network

    Approximately 20 leading U.S. cancer centers

    Participating Centers

    MD Anderson Cancer Center

    Johns Hopkins University

    City of Hope

    Northwestern University

    University of Colorado

    Augusta University

    UCLA

    + Additional Sites

    source: biospace.com

    Why It Matters

    Addressing an Unmet Need:

    Utidelone is a synthetic epothilone designed to cross the blood–brain barrier, addressing a significant unmet need in patients with central nervous system involvement.

    source: biospace.com

    Brain metastases represent a major treatment challenge in breast cancer, with limited options that effectively penetrate the CNS. Utidelone's ability to cross the blood-brain barrier could provide a new therapeutic avenue for this difficult-to-treat patient population.

    Scientific Background

    • Epothilone class: Microtubule-stabilizing agents similar to taxanes but with distinct properties
    • CNS penetration: Engineered to cross the blood-brain barrier unlike conventional taxanes
    • Combination rationale: Capecitabine provides synergistic anti-tumor activity with favorable tolerability

    What to Watch

    • Intracranial response rates; primary efficacy signal for CNS activity
    • Extracranial disease control for systemic efficacy assessment
    • Safety profile of the combination regimen, particularly neurotoxicity
    • Progression-free survival in this high-risk patient population

    Kitsa Platform Relevance

    Pivotal oncology trials with CNS endpoints require experienced neuro-oncology sites and rapid patient identification. Kitsa's AI-powered platform enables:

    • Identification of HER2-negative breast cancer patients with documented brain metastases
    • Site selection based on neuro-oncology and brain imaging capabilities
    • Accelerated enrollment through EHR-integrated patient screening

    Stay updated on the latest trial developments

    Optimize your trial enrollment

    Keep exploring

    Recommended next